Ocugen IncChange company Symbol lookupSelect an option...OCGN Ocugen IncHYHG.EU ProShares High Yield-Interest Rate HedgedDIDIY DiDi Global IncAWK American Water Works Company IncASO Academy Sports and Outdoors IncGAB Gabelli Equity TrustSTRC Sarcos Technology and Robotics CorpRLMD Relmada Therapeutics IncLMND Lemonade IncNAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025Go
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
HYHG.EU ProShares High Yield-Interest Rate Hedged
DIDIY DiDi Global Inc
AWK American Water Works Company Inc
ASO Academy Sports and Outdoors Inc
GAB Gabelli Equity Trust
STRC Sarcos Technology and Robotics Corp
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
Health Care : Biotechnology | Small Cap Growth
Company profileOcugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Met Consensus (Q2 ending 06/2022) | Next Earnings Announcement | ||||
|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 5, 2022 | -$0.09 | Q2 Estimate range of 5 analysts | -$0.10 to -$0.06 | Q3 Earnings will announce | (Unconfirmed) November 7, 2022 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
OCGN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.